Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:57 PM
Ignite Modification Date:
2025-12-24 @ 10:57 PM
NCT ID:
NCT02540369
Eligibility Criteria:
Inclusion Criteria:
* Age: \>= 18 years of age
* Male or female
* Patients with wet AMD (wet age-related macular degeneration) or Diabetic macular edema (DME) who will be treated by intravitreal aflibercept according to the Canadian Product monograph recommendations and routine clinical practice.
* Decision to treat with intravitreal aflibercept prior to patient enrolment as per the physician's routine clinical practice.
Exclusion Criteria:
* Patients participating in an investigational program with interventions outside of routine clinical practice.
* Patients currently being treated with intravitreal aflibercept. This study will only include patients new to intravitreal aflibercept, both naïve and previously treated with other anti-VEGF therapies.
* Patients who are hypersensitive to this drug, to any ingredient in the formulation, or to any component of the container.
* Patients who are hypersensitive to this drug, to any ingredient in the formulation, or to any component of the container.
* Ocular or peri-ocular infection
* Active intraocular inflammation
* Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
* Any concomitant therapy with another agent to treat wet AMD or DME in the study eye.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02540369
Study Brief:
Protocol Section:
NCT02540369